Blood nicotine and cotinine concentrations were measured in 27 volunteers before and after taking snuff. Within 10 minutes after snuffing blood nicotine concentrations were comparable to those obtained after the 10 minutes or so that it takes to smoke a cigarette. Nicotine intake from snuffing was related to the experience of the snuffer. In daily and occasional snuffers increases in plasma nicotine concentrations averaged 77-7 and 12 3 nmol/l (12 6 and 2 0 ng/ml) respectively, while the novices showed no appreciable increase. The increase shown by the daily snuffers was comparable to the average increase of 62 3 nmol/l (101 ng/ml) obtained from a single cigarette by a group of heavy smokers. The peak nicotine concentrations in the daily snuffers were also similar to the peak values in 136 heavy smokers-222-6 and 226-3 nmol/l (36 1 and 36-7 ng/ml), respectively. Unusual multiple-dose snuffing produced massive increases in plasma nicotine to concentrations that have never been recorded in smokers.
Introduction
In a preliminary study' we showed that the absorption of nicotine from a single pinch of snuff taken by an experienced snuffer was extremely rapid and produced plasma nicotine concentrations comparable to those obtained from cigarette smoking. This suggested that snuff might be an acceptable and relatively harmless substitute for smokers who have difficulty giving up cigarettes. The preliminary study was based on the plasma nicotine concentrations of a single snuffer. We now present the results from a sample of snuff users. We are aware of only one other study of nicotine intake from nasal snuff, and this was limited to measurements of nicotine and its metabolites in urine. 2 
Subjects and methods
Although there are reportedly about 500 000 regular snuff users in Britain,3 only three have attended our clinic over the past 10 years. On 24 taking champion was present for our visit and volunteered for the study.
Twenty-seven volunteers took part in the study. Four had never used snuff before ("virgin" snuffers), 12 were occasional snuffers, and 11 took snuff daily. Table I gives their smoking habits and endexpired air carbon monoxide concentrations, which reflected their recent smoking and inhalation.4 They had been smoking and snuffing as usual up to the time of the study (6 pm to 10 pm).
Venous blood samples were taken one to two minutes before a pinch of snuff and then repeated between six and 17 minutes after taking the snuff (mean 101 + SD 2-4 minutes). Five subjects took multiple doses of snuff, two of them according to championship rules (see figs 2 and 3). In these two subjects serial blood samples were taken using a butterfly cannula. Blood samples were kept in a refrigerator for one to three hours before centrifuging. The plasma was then frozen until analysed for nicotine5 and cotinine.6 The plasma nicotine and cotinine concentrations were compared with those of heavy cigarette smokers attending the smokers' clinic at the Maudsley Hospital. Conversion: SI to traditional units-Nicotine: 1 nmol/l 0 16 ng/ml. Cotinine: 1 nmol/l0l175 ng/ml. nmol/1 (129-3 ng/ml) plasma, as was shown in the British champion snuffer, has never been recorded before in man. His maximum plasma cotinine concentration (5863-0 nmol/l; 1028-3 ng/ml) was also a record. The highest concentrations found in over 400 heavy smokers attending our clinic were 474-7 nmol/l (77-0 ng/ml) and 4310-0 nmol/l (756-0 ng/ml) for nicotine and cotinine, respectively.
Results
The similarity of the plasma nicotine concentrations in regular smokers and daily snuffers might be merely coincidental. On the other hand, possibly the concentration of nicotine has a controlling influence on the rate and amount of self-dosage of these two very different forms of tobacco use. To find one group of people who sniff powdered tobacco into their noses have similar blood nicotine concentrations to those of another group who burn it to inhale its smoke suggests that the concentration of nicotine has some controlling influence. It would be a remarkable coincidence if factors such as flavour, strength of tobacco, social influences, and so on just happened to produce similar blood nicotine concentrations resulting from two such different behaviours. The most plausible explanation is that the rituals of snuffing and smoking are determined by the nicotine concentrations that they produce. Whether the use is regulated to obtain the rewards of a given concentration of nicotine or to avoid the unpleasant effects of excessive nicotine intake is another equally important question that remains to be answered. 8 From our results snuff use may clearly be an efficient method of nicotine intake. This suggests that it might prove sufficiently acceptable to smokers, not only as a temporary substitute to help those who are trying to give up smoking but as a long-term alternative to continued cigarette smoking. It is important, therefore, to consider the health implications of switching from cigarette smoking to long-term snuff use.
Unlike tobacco smoke, snuff is free of tar and harmful gases such as carbon monoxide and nitrogen oxides. Since it cannot be inhaled into the lungs, there is no risk of lung cancer, bronchitis, and emphysema. Indeed, the US Surgeon General's report of 1979 stated that "snuff and chewing tobacco have not been found to increase mortality (either overall or cause-specific) in the United States."9 This view is probably oversanguine.
These forms of tobacco use produce oral leucoplakia,"' and snuff dipping may cause oral cancer." '' Snuff dipping is the predominant form of snuff use in the USA and Scandinavian countries. It consists in the placement and retention of finely ground tobacco ("wet snuff") in the oral vestibule between the gums and lower lip. This contrasts with snuff use in Britain, which consists in sniffing powdered tobacco ("dry snuff") into the nose. Wet snuff contains nitrosonornicotine, which is carcinogenic in rats."' '4 There is no reason to expect that nitrosonornicotine is not also present in the dry snuff used in Britain. Though we are not aware of any direct evidence, prolonged heavy use of dry snuff might well carry a slight risk of nasopharyngeal cancer.
The position with coronary heart disease is not clear. It is not known whether nicotine or carbon monoxide is the major culprit responsible for cigarette-induced coronary heart disease.
If it is carbon monoxide a switch to snuff would reduce the risk substantially, but even if nicotine plays a part our results show that the intake from snuff is no greater than from smoking.
In conclusion, the rapid absorption of nicotine from snuff confirms its potential as an acceptable substitute for smoking. Switching from cigarettes to snuff would substantially reduce the risk of lung cancer, bronchitis, emphysema, and possibly coronary heart disease as well, at the cost of a slight increase in the risk of cancer of the nasopharynx (or oral cavity in the case of wet snuff). Another advantage of snuff is that it does not contaminate the atmosphere for non-users.
We thank Garry Cox, of Wellington, Somerset, for organising the meeting of volunteer snuff users and for arranging use of the facilities of the local health centre, Dr P D Dawkins for allowing us to centrifuge the blood samples at Musgrove Hospital in Taunton A S JONES, PHD, professor of chemistry R T WALKER, PHD, lecturer of chemistry zoster virus infections. There are also several other 5-substituted deoxyuridine derivatives, such as 5-vinyl-deoxyuridine (VDU), which show significant anti-herpes activity, but these compounds do not appear to be sufficiently selective in their antiviral action. From comparative studies of the potency and cytotoxicity of these compounds in cell culture, BVDU has emerged as the most potent and most selective anti-herpes agent. ' Since IDU, TFT, and BVDU are all thymidine analogues, they might act as mutagens and hence induce permanent changes in the cellular genome. Sister chromatid exchange is a sensitive indicator of mutagenesis.' We therefore examined IDU, TFT, and BVDU for their capacity to induce sister chromatid exchange in human lymphocytes and fibroblasts.
Methods
Sister chromatid exchange was scored as described previously.3 IDU was from Ludeco (Brussels) and TFT from Sigma Chemical Co, and BVDU was synthesised as described.' VDU, 5-vinyluridine, and 5-vinyluracil were included as reference materials.'
The nucleoside analogues were incubated for 48 hours with human (peripheral blood) lymphocytes and 72 hours with human (fetal lung) fibroblasts at concentrations ranging from 0 05 to 50 mg/l in the presence of 3 mg/l bromo-deoxyuridine. Ethylmethane sulphonate (Sigma Chemical Co) served as a positive control: it was added at 60 mg/l, a concentration known to induce a significant increase in the number of sister chromatid exchanges.3
Results
In lymphocytes BVDU and IDU did not increase the number of sister chromatid exchanges until the concentration was raised to 50 mg/l (see table) . TFT, however, caused a significant increase in the exchange rate at a concentration of 0-5 mg/l; and at 5 ig/ml it proved even more effective in inducing exchange than the standard mutagen ethylmethane sulphonate.
While not very effective in lymphocytes, VDU turned out to be an exquisitely potent inducer of exchange in fibroblasts, where it caused a significant increase in exchange frequency at concentrations of 0 5 and 5 mg/l, while BVDU and IDU failed to do so. BVDU and IDU increased the frequency of exchange in fibroblasts only at a concentration of 50 mg/l.
The level of significance was assessed by Student's t test, and, since the individual values were not distributed normally, significance was also monitored by the Poisson distribution.
